ClinicalTrials.gg
RecruitingNCT05414409Updated Aug 21, 2026

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

A Phase 2 interventional study of Metformin in Type 1 Diabetes and Obesity, sponsored by Heba M. Ismail. Recruiting at 1 site in United States. Open to participants aged 11 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Heba M. Ismail · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Non-randomized
Ages
11 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing metformin in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. Metformin · Diabetes Mellitus, Type 1.

Planned enrollment
5th of 22
114 · median 43
Started
2022
with 1 other
Phase 2
Only one
of the 22
Registered
22nd of 22
by date
Lead sponsor
1 of 22
Heba M. Ismail

Among the 22 studies testing metformin in Diabetes Mellitus, Type 1, this one is the 5th largest by planned enrollment, is one of 2 that started in 2022, is the only one in phase 2, and was the 22nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 22 studies testing metformin in Diabetes Mellitus, Type 1 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 11 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing metformin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.

03

Conditions studied

  • Type 1 Diabetes
  • Obesity
04

Who can participate

Ages eligible
11 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Overweight/obese youth 11-18 years of age with T1D at time of enrollment.
  2. Lean youth 11-18 years of age with T1D at time of enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and by genetic/antibody testing).
  2. History of ongoing infection or antibiotic treatment within the past month;
  3. History of immune-compromise, recurrent infections, intake (inhaled or oral forms) or other use in the past 6 months.
  4. History of chronic gastrointestinal disease and active within the past 6 months, possible or confirmed celiac disease.
  5. Participation in any research intervention trials within the past 3 months.
  6. History of treatment or use of metformin, a type 2 diabetes medication.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
114 participants (estimated)

Study arms

  • No intervention
    Comparison of microbiome by BMI Category

    The gut microbiome and metabolites of 42 lean and 42 overweight/obese youth with type 1 diabetes will be evaluated cross-sectionally.

  • Experimental
    Metformin

    This is a group of 30 youth with type 1 diabetes and overweight/obesity who will receive metformin for 6 months.

    Drug: Metformin

Interventions

  • Metformin is an oral medication that improves insulin sensitivity.

06

What researchers measure

Primary outcomes

  1. Differences in the gut microbiome in lean and overweight/obese youth with type 1 diabetes

    cross sectional comparison of stool microbiome using metagenomic sequencing data

    Time frame: Baseline

  2. Differences in the gut microbial metabolites in lean and overweight/obese youth with type 1 diabetes

    The investigators will measure and compare the stool and serum short chain fatty acids using mass spectrometry

    Time frame: Baseline

  3. Differences in the gut microbial metabolites in lean and overweight/obese youth with type 1 diabetes

    The investigators will measure and compare the stool and serum secondary bile acids using mass spectrometry

    Time frame: Baseline

  4. Changes in the gut microbiome in overweight/obese youth with type 1 diabetes in response to metformin

    longitudinal comparison before and after taking metformin for 6 months, stool samples will be collected at baseline, 3 months and 6 months and sequenced for microbiome profile using metagenomic sequencing

    Time frame: Baseline, Month 3, and Month 6

  5. Changes in the gut microbial metabolites in overweight/obese youth with type 1 in response to metformin

    The investigators will measure and compare the stool and serum metabolites (short chain fatty acids and secondary bile acids) before, during and after 6 months of daily metformin therapy using mass spectrometry

    Time frame: Baseline, Month 3, and Month 6

Secondary outcomes

  1. Differences in measures of C-peptide as a measure of beta cell health in lean and overweight/obeseT1D youth

    The investigators will measure serum C-peptide to calculate a ratio of proinsulin to C-peptide as a marker of beta cell health. These measures will then be compared between the lean and obese T1D youth.

    Time frame: Baseline

  2. Differences in measures Proinsulin as a measure of beta cell health in lean and overweight/obeseT1D youth

    The investigators will measure serum proinsulin and calculate a ratio of proinsulin to C-peptide as a marker of beta cell health. These measures will then be compared between the lean and obese T1D youth.

    Time frame: Baseline

  3. Differences in measures of insulin sensitivity in lean and overweight/obese T1D youth

    Insulin sensitivity will be assessed in individuals using the estimated insulin sensitivity score (eIS), which is based on waist circumference (cm), HbA1c (%) and triglycerides (mg/dl)

    Time frame: Baseline

  4. Changes in measures of C-peptide as a measure of beta cell health in overweight/obese T1D youth in response to metformin

    Serum C-peptide will be used to calculate proinsulin to C-peptide ratio as a measure of beta cell health before and after metformin therapy

    Time frame: Baseline, Month 3, and Month 6

  5. Changes in measures of proinsulin as a measure of beta cell health in overweight/obese T1D youth in response to metformin

    Serum proinsulin will be used to calculate proinsulin to C-peptide ratio as a measure of beta cell health before and after metformin therapy

    Time frame: Baseline, Month 3, and Month 6

  6. Changes in measures of insulin sensitivity in overweight/obese T1D youth in response to metformin

    Estimated insulin sensitivity score will be used to assess response metformin therapy

    Time frame: Baseline, Month 3, and Month 6

  7. Changes in measures of beta cell function using a timed mixed meal tolerance test

    Participants in the metformin trial will undergo a standard 2-hour mixed meal tolerance test at baseline and after 6 months of oral metformin therapy

    Time frame: Baseline and Month 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Nov 2026, 49 months after the start.

Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 49 months is close to that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2022
First posted
Jun 10, 2022
StartActual
Sep 30, 2022
Primary completionEst.
Nov 2, 2026
CompletionEst.
Mar 1, 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05414409
Lead sponsor
Heba M. Ismail
Responsible party
Heba M. Ismail (Assistant Professor of Pediatrics, Indiana University) — Sponsor-investigator
First posted
Jun 10, 2022
Start date
Sep 30, 2022
Primary completion
Nov 2, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Heba M Ismail
Contact
heismail@iu.edu
317-274-2114
HI Team
Contact
hiteam@iu.edu
317-274-2114

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion